RELENZA is a Respiratory (inhalation) Powder in the Human Prescription Drug category. It is labeled and distributed by Dispensing Solutions Inc.. The primary component is Zanamivir.
| Product ID | 68258-3030_342b7e19-49d6-4d0b-950a-cc00f4b79924 |
| NDC | 68258-3030 |
| Product Type | Human Prescription Drug |
| Proprietary Name | RELENZA |
| Generic Name | Zanamivir |
| Dosage Form | Powder |
| Route of Administration | RESPIRATORY (INHALATION) |
| Marketing Start Date | 2002-12-22 |
| Marketing Category | NDA / NDA |
| Application Number | NDA021036 |
| Labeler Name | Dispensing Solutions Inc. |
| Substance Name | ZANAMIVIR |
| Active Ingredient Strength | 5 mg/1 |
| Pharm Classes | Neuraminidase Inhibitor [EPC],Neuraminidase Inhibitors [MoA] |
| NDC Exclude Flag | E |
| Listing Certified Through | 2017-12-31 |
| Marketing Start Date | 2002-12-22 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA021036 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2002-12-22 |
| Inactivation Date | 2019-10-21 |
| Ingredient | Strength |
|---|---|
| ZANAMIVIR | 5 mg/1 |
| SPL SET ID: | 12ff22f6-20b5-4fa8-9028-58f87e169ff5 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0173-0681 | RELENZA | zanamivir |
| 68258-3030 | RELENZA | zanamivir |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() RELENZA 78452022 3049319 Live/Registered |
Glaxo Group Limited 2004-07-16 |
![]() RELENZA 75975285 2101718 Dead/Cancelled |
Glaxo Group Limited 1994-06-21 |
![]() RELENZA 74540557 not registered Dead/Abandoned |
Glaxo Group Limited 1994-06-21 |